Save on Acid Reflux Medications in New York
Compare Acid Reflux Medications prices across New York pharmacies. Save up to 64% — no insurance required.
Top Acid Reflux Medications for New York Residents
Omeprazole (Prilosec)
Pantoprazole (Protonix)
Esomeprazole (Nexium)
Dexlansoprazole (Dexilant)
Famotidine (Pepcid)
New York Prescription Assistance Programs
EPIC (Elderly Pharmaceutical Insurance Coverage)
Helps eligible New York seniors pay Medicare Part D premiums, deductibles, and co-pays. Also covers some medications not covered by Part D.
Eligibility: New York residents aged 65+ with income up to $75,000/year (single) or $100,000/year (married). Call 1-800-332-3742 to enroll.
New York Medicaid Rx
Comprehensive prescription drug coverage through New York's Medicaid managed care plans for eligible residents.
Eligibility: Low-income New York adults up to 138% FPL, children, pregnant women, seniors, and people with disabilities.
Frequently Asked Questions
Is omeprazole cheap as a generic?
Generic omeprazole is available OTC for around $10–$15/month and prescription generics are even cheaper per-unit via ScriptUnlock bids — often under $10 for a 30-day supply.
Should I use a PPI or H2 blocker for acid reflux?
PPIs are more potent and appropriate for GERD; H2 blockers like famotidine work well for occasional reflux. Your doctor or pharmacist can guide the choice — ScriptUnlock helps with pricing for either.
How much can I save switching from Nexium to esomeprazole?
Brand Nexium can cost $200–$300/month without insurance; generic esomeprazole is typically $20–$40. ScriptUnlock bids make that comparison instant and actionable.
Can I use ScriptUnlock for compounded omeprazole suspension?
Yes. Compounded omeprazole for pediatric or NG-tube patients can be sourced through ScriptUnlock compounding pharmacy partners.
Is long-term PPI use safe?
PPIs are generally safe for appropriate indications but should be used at the lowest effective dose. Discuss duration and tapering with your prescriber — ScriptUnlock helps with the cost, not the clinical decision.